key: cord-0704811-s9fvsrv3
authors: Connors, Jean M.; Moll, Matthew; Levy, Jerrold H.
title: Interpreting recent clinical studies for COVID-19: A continual process with more new data
date: 2021-12-24
journal: Anaesth Crit Care Pain Med
DOI: 10.1016/j.accpm.2021.101016
sha: 7574f856db24d029b694ba6001253f545c5d2823
doc_id: 704811
cord_uid: s9fvsrv3

nan

. In moderately ill patients, therapeutic heparin did not reduce the primary outcome of progression to mechanical ventilation, ECMO, or death, but decreased 28-day mortality with a low risk of major bleeding.

However, many clinicians viewed the RAPID trial as negative because the primary outcome events were low, the 28-day mortality signal was small, and the study was underpowered.

More recently, the parallel Therapeutic Anticoagulation with Heparin in Critically Ill Patients with COVID-19 adaptive, multiplatform, RCT (n = 1098) evaluated critically ill patients receiving therapeutic or thromboprophylaxis doses with standard management (6) . The primary outcome was organ support-free days without cardiopulmonary support to day 21 and surviving to hospital discharge. The study was stopped due to futility, as survival to hospital discharge was 62.7% vs. 64.5%, with no difference in organ support free days.

The other parallel RCT evaluated hospitalized non-critically ill COVID-19 patients, defined as an absence of critical care level organ support on enrollment (7) . Patients were randomized to receive either therapeutic-dose or usual-care pharmacologic thromboprophylaxis with heparins.

The primary outcome was organ support-free days: days free of cardiovascular or respiratory organ support to day 21 among patients who survived to hospital discharge. The trial was also stopped after 2219 patients due to failure to meet prespecified criteria for the superiority of therapeutic-dose anticoagulation. However, the adjusted absolute between-group difference in survival until hospital discharge without organ support in the therapeutic-dose anticoagulation was only 4.0%, with major bleeding in 1.9% in therapeutic dose compared to 0.9% in the thromboprophylaxis groups. How do we interpret this evolution of clinical management strategies based on recent randomized studies? There is growing data that therapeutic anticoagulation dosing has a signal for decreased VTE (macrovascular thrombosis) in hospitalized patients who have advanced to a critically ill state. It is the question of "turning the tide" of COVID-19, that is, whether higher levels of anticoagulation can prevent microvascular thrombotic progression and multiorgan injury.

Adding complexity to interpreting the data is defining critical illness, a term that we understand intuitively but is more difficult to define. In general, we believe critical illness represents a requirement for at least one organ support (e.g., oxygen for acute lung injury or vasoconstrictor and/or inotropic agents for shock), and the consideration the patient is at an increased risk for deterioration requiring additional support. Although most assume that ICU patients are critically ill, ICU admission criteria vary among institutions and are complicated by ICU bed availability in Page 6 of 9 J o u r n a l P r e -p r o o f this era of COVID-19. In the multiplatform studies, the definition of non-severe hospitalized patient was an oxygen requirement of < 6 L/min (7) .

Further, in the multiplatform non-critically ill patient trial, the design and analysis leave additional questions regarding the significance of avoiding organ support if there is no difference in mortality; in this study, most patients survived to hospital discharge: 92.7%-therapeutic dose and 91.8%-standard of care (OR = 1.21 (0.87-1.68), an 87.1% superiority probability for therapeutic dose heparin. However, the difference between organ support-free days was only 4% at 21 days, and median value for organ support-free days 22 in both groups. For non-ICU ward patients, the therapeutic heparin arm appears to have a beneficial effect with Bayesian adjusted OR = 1.27 (95%; 1.03-1.58) (7).

These results are controversial for several reasons. First, participants assigned to each trial arm were recalculated based on a single interim analysis in 2020 to favor randomization to the therapeutic dose arm. This approach is called response-adaptive randomization. This approach theoretically provides therapeutic advantages to study participants, however, it can also introduce selection bias, counteract initial randomization benefits, reduce total absolute numbers of individuals assigned to the favored arm, and lead to challenges interpreting the final results (9, 10) . The chance for bias is greater when based on fewer or a single interim analysis, as was done in this trial. Second, it is challenging for a clinician to gauge whether an individual patient would have qualified for the trial. For example, participants who were thought to need J o u r n a l P r e -p r o o f hospitalization for 72 hours or less were excluded, some sites only enrolled patients within 72 hours of hospital admission, while others within 14 days of admission. Third, determining the benefits and risks of therapeutic dose prophylaxis for individual patients is challenging since major bleeding events were higher in the therapeutic dose arm. Although planned analyses to further assess outcomes/benefits are underway, guidelines vary widely.

For moderately ill COVID-19 patients, the difficulty determining which patients benefit from higher dose anticoagulation, the possibility of bias explaining the observed beneficial effects, and the elevated major bleeding risks make it challenging to recommend this strategy. Other factors should be considered, including potential differences between LMWH and UFH and concerns regarding heparin resistance in the COVID-19 patients (11) . The current guidelines, as it makes intuitive sense that as the acute inflammatory response declines, so does the associated hypercoagulability but now with the potential for increased bleeding that includes added risks from prolonged ICU level care.

In summary, as we continue to gather more data about the role of anticoagulation in COVID-19 from additional RCTs in progress, guideline and guidance documents will likely continue to Page 8 of 9 J o u r n a l P r e -p r o o f evolve. In addition, the critical role of vaccinations to prevent or attenuate this complex thromboinflammatory response of COVID-19 and the use of specific antiviral therapies that are rapidly evolving will further influence future recommendations.

Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis

Trends and diagnostic value of D-dimer levels in patients hospitalized with coronavirus disease

) § From the French working group on perioperative haemostasis (GIHP) and the French study group on thrombosis and haemostasis (GFHT), in collaboration with the French Society of Anaesthesia and Intensive Care (SFAR)

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

VTE in ICU Patients With COVID-19

Resist the Temptation of Response-Adaptive Randomization

Critical concepts in adaptive clinical trials

Heparin Resistance -Clinical Perspectives and Management Strategies